The United States Department of Energy issued a report entitled “Top Value Added Chemicals from Biomass”. The report confirms the $10's of billions market opportunities that exist for innovators able to deliver these high value chemicals in a cost effective manner. The biological production of these chemicals changes the cost structure well beyond the single digit percentages typical of today's chemical industry, up to 50% or even an order of magnitude in cost reduction. As in the biotech industry, perfecting even one of these molecules forms the basis for a paradigm shifting industrial biotechnology corporation.
Kalion is an early stage industrial biotech company that will transform the traditional chemical industry by providing low-cost access to glucaric acid and S-3-hydroxybutyrolactone (3-HBL) using traditional, green, fermentation technology. Glucaric acid and 3-HBL were identified as “Top Value Added Chemicals from Biomass” and multi-billion dollar markets for use of the two chemicals are limited by cost and availability (2004 DOE report).
Our team is composed of a diverse set of individuals with broad and relevant experience.
He formerly worked at McKinsey & Co. and several different startups. While at McKinsey, one of his key assignments was to develop a strategy for a key bioengineered product for a Fortune 500 company. The strategy proved widely successful for the company, and for over a decade, has driven billions in profits. He received his MA in Philosophy, Politics and Economics while studying at Oxford University on a Rhodes Scholarship. He received two S.B.'s from MIT, one in Electrical Engineering and one in Science, Technology and Society. He is a former member of the Massachussets Institute of Technology's board of trustees and Great Lakes Industrial Technology Council (GLITeC) Advisory Board.SEND ME AN EMAIL
Dr. Connors has over 25 years of experience in the bioprocess development field: previously as a senior scientist at Merck Research Labs, as the owner/president of Phoenix BioConsulting, LLC, and as a member of Drew University’s Research Institute for Scientists Emeriti (RISE). His scientific experience encompasses the development of microbial and mammalian cell bioprocesses for the production of bioactive small molecules, biochemicals, therapeutic proteins, and vaccine antigens. Neal received his Ph.D. in microbiology from Ohio State and has been a contributing author on numerous peer-reviewed papers, book chapters, patents, and conference abstracts. He has been an active member of the Society for Industrial Microbiology and Biotechnology for several years serving as a president, director, program chair for the 2006 annual meeting, and 2003 fermentation technology meeting. He also serves on the editorial boards for the Journal of Industrial Microbiology and Biotechnology and Enzyme and Microbial Technology and is a regular reviewer for Applied Microbiology and Biotechnology.SEND ME AN EMAIL
Dr. Watson has almost thirty years of experience in the pharmaceutical and biotechnology industries. Dr. Watson is currently the Chief Executive Officer of Estabrook Pharmaceuticals, Inc. He is also an Executive-in-Residence at Oxford Bioscience Partners and serves on the boards of several biotech companies. Most recently, Dr. Watson was Vice President of Business Development at SmartCells, Inc. where he negotiated the sale of the company to Merck & Co. for $500M in upfront and milestone payments. His prior appointments include Chief Business Officer and Executive Vice President at Elixir Pharmaceuticals, Inc., Senior Vice President of Corporate Development at Cubist Pharmaceuticals, Inc. and Senior Vice President, IP and Licensing at Nycomed Amersham plc. (now General Electric Co.) and he previously held a variety of scientific, R&D and business management positions at Nycomed AS, Salutar Inc. and DuPont Pharmaceuticals, Inc. where he invented the brain imaging drug NeuroLite. Dr Watson received his B.Sc. (Hons) from the University of N.S.W. in Sydney, Australia, his Ph.D. in Chemistry from the Australian National University in Canberra, Australia and carried out postdoctoral research in the U.K. and at Harvard University. He also obtained an M.B.A. from Northeastern University in Boston.SEND ME AN EMAIL